Related Experiment Video
Updated: Jun 4, 2026

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
Supramolecular devices to improve the treatment of brain diseases
Donatella Paolino1, Donato Cosco, Roberto Molinaro
1Department of Experimental and Clinical Medicine, Faculty of Medicine, University 'Magna Græcia' of Catanzaro, Campus Universitario 'S. Venuta', Building of BioSciences, Viale S. Venuta, I-88100 Germaneto (CZ), Italy.
Abstract:
The blood-brain barrier (BBB) hinders the accumulation of active compounds in the central nervous system, thus decreasing their therapeutic effectiveness. To overcome this obstacle, interesting supramolecular nanodevices are herein considered. These systems have many advantages over the conventional formulations, such as having structures made up of biocompatible and biodegradable materials, the possibility of bypassing the BBB in a non-invasive manner (without structural modifications) and the possibility of being structurally modified to modulate the biopharmaceutical properties of the encapsulated compounds. Polymolecular (liposomes, niosomes, nanogels) and oligomolecular (cyclodextrins) devices have potential clinical applications in brain drug delivery, being capable of active targeting that can concentrate bioactives in the brain.
Related Concept Videos
Brain Imaging
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
The Blood-brain Barrier
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

